https://scholars.lib.ntu.edu.tw/handle/123456789/496053
標題: | Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus | 作者: | CHIN-HSIAO TSENG | 關鍵字: | Diabetes mellitus; Metformin; Nasopharyngeal cancer; Taiwan | 公開日期: | 2018 | 出版社: | W.B. Saunders | 卷: | 85 | 起(迄)頁: | 223-226 | 來源出版物: | Metabolism: Clinical and Experimental | 摘要: | Background: Metformin has anticancer effects, but whether it can reduce the risk of nasopharyngeal cancer (NPC) is not known. Methods: A total of 15,486 ever-users and 15,486 never-users of metformin matched by propensity score were enrolled from among patients with new-onset type 2 diabetes mellitus diagnosed during the period 1999–2005 and who were found in the reimbursement database of Taiwan's National Health Insurance. The patients were followed until December 31, 2011. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity scores. Results: NPC incidence was 33.41 and 106.04 per 100,000 person-years in ever-users and never-users, respectively. The overall hazard ratio (95% confidence interval) of 0.312 (0.197–0.494) favored a significantly lower risk among metformin ever-users than in never-users. Hazard ratios comparing the first (<26.03 months), second (26.03–58.03 months) and third (>58.03 months) tertiles of cumulative duration of metformin use to never-users were 0.690 (0.389–1.224), 0.187 (0.076–0.463) and 0.168 (0.068–0.415), respectively. A significantly lower risk of NPC was consistently observed among metformin users in subgroup analyses of age (<50 years and ?50 years), sex (men and women), and patients with or without nephropathy, liver diseases or diseases of the esophagus, stomach, and duodenum, respectively. Conclusions: Metformin use is associated with a significantly lower risk of NPC. ? 2018 Elsevier Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046618892&doi=10.1016%2fj.metabol.2018.04.009&partnerID=40&md5=cecc7c1ae35689d20d4d00f6a10565a1 https://scholars.lib.ntu.edu.tw/handle/123456789/496053 |
ISSN: | 0026-0495 | DOI: | 10.1016/j.metabol.2018.04.009 | SDG/關鍵字: | metformin; antidiabetic agent; metformin; adult; age; Article; cancer incidence; cohort analysis; confidence interval; controlled study; diabetic patient; duodenum disease; esophagus disease; female; follow up; hazard ratio; human; kidney disease; liver disease; major clinical study; male; nasopharynx cancer; non insulin dependent diabetes mellitus; priority journal; propensity score; reimbursement; sex; stomach disease; treatment duration; complication; factual database; incidence; middle aged; nasopharynx tumor; non insulin dependent diabetes mellitus; risk; Taiwan; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Nasopharyngeal Neoplasms; Risk; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。